Primary Bioscience is addressing one of biology’s biggest blind spots: we still can’t directly read proteins, the molecules that actually drive health and disease. Existing tools like mass spectrometry and DNA inference leave major gaps, missing key amino acids and chemical modifications that define protein function. Primary Bioscience is developing the first de novo protein sequencing instrument that reads single molecules end-to-end. By combining surface-enhanced Raman spectroscopy (SERS), innovative chemistry, and AI-based signal decoding, it captures all twenty amino acids and their modifications with single-molecule precision. This breakthrough enables true, full-coverage proteomics, unlocking discoveries in diagnostics, drug targets, and therapeutics that have been invisible until now.

Materia Bioworks is accelerating the world’s transition away from plastics by using AI to help brands design and manufacture high-performance biodegradable products. Despite 100s of bioplastics on the market, developing sustainable products remains slow, expensive, and complex,often taking years and millions of dollars.

Materia’s AI-driven formulation and manufacturing platform replaces that trial-and-error with data-guided, drop-in solutions that fit seamlessly into existing workflows, enabling brands to launch sustainable products 3x faster and 10x cheaper.

Founded by the team behind a Series A bioplastics company that co-developed 4 biodegradable products with Fortune 500s, Materia is building the infrastructure to make sustainable materials development as fast, predictable, and scalable as software, turning the $1T plastics industry into a platform for circular innovation.

iOrgan Bio is redefining how human cells are made by turning biology into an industrial, data-defined process. Built on technology from Weill Cornell Medicine and the Terasaki Institute, the company’s CellForge platform uses AI-driven, multi-omics feedback control to guide cells toward exact target states without genetic modification. This enables reproducible manufacturing of any human cell type or organoid with unmatched bioequivalence and cost efficiency. By standardizing living cell production, iOrgan Bio provides the foundation for scalable disease modeling, regenerative medicine, and cell therapy manufacturing—at up to 100× lower cost than today’s methods. Led by experts from MD Anderson, Weill Cornell, and top biotech companies, iOrgan Bio is transforming human cells from bespoke materials into reliable, mass-manufactured products.

RizLab has developed an ultra-compact, all-electronic cytometer capable of quantifying white blood cells and the key subtypes in minutes with just a prick of the finger—with 97% accuracy.

RizLab’s CytoTracker can quantify important WBC parameters such as the total white blood cell count, the absolute neutrophil count, and the absolute lymphocyte count, along with the percentages. Existing FDA-approved, commercially available analyzers for white blood cell count analysis are expensive, bulky, and require professionals to use.

Bioeutectics is a green chemistry company pioneering a new generation of high-performance solvents based on advanced eutectic systems. We replace hazardous petrochemical solvents with safer, biodegradable alternatives that meet or exceed industry benchmarks—while remaining highly cost-competitive at scale. Our approach proves that sustainability and economic performance can go hand in hand.

A cornerstone of our platform is the development of Active NADES (Natural Deep Eutectic Systems), engineered to enhance the functional performance of active ingredients. By boosting the solubility, stability, and bioavailability of actives, our systems can increase performance by up to 8x while reducing formulation costs by as much as 45%. This creates a compelling value proposition for industries such as flavors and fragrances, cosmetics, and agrochemicals, where both efficacy and margin optimization are critical.

In advanced materials and circularity, our proprietary Nylon Recovery Solvent provides a safer and more efficient alternative to formic acid. It dissolves nylon 6 and 6.6 while preserving polymer integrity, preventing equipment corrosion, and enabling selective separation of complex textile blends for true material recovery.

With validated performance, scalable manufacturing, and strong commercial potential, Bioeutectics is redefining solvent chemistry—delivering solutions that are safer, more efficient, and economically superior.

Klona Biotech is redefining reconstructive medicine with 3D-printed, personalized implants for mechanically demanding tissues like ligaments, tendons, and cartilage. Millions of patients each year require grafts for these tissues, yet donor shortages and graft failure remain major barriers to recovery.

Klona’s proprietary bioprinting platform integrates fiber-reinforced “gel-textile” composites – materials up to twenty times stronger than standard bioprints while remaining compatible with living cells. The result is regenerative implants that combine biological function with real mechanical strength.

Founded by Dylan Yeo (University of Oxford) and Thomas Groom (Imperial College London), Klona is developing its first ligament implant and next-generation printer system to enable hospitals to bioprint patient-specific tissues on demand.

Industrial pollution and mineral shortages have created an urgent need for sustainable cleanup and resource recovery. Conventional methods rely on excavation and landfill disposal—slow, costly, and damaging to ecosystems.

Deep Root BioLabs reprograms plants from the inside out. Using engineered endophytes, microbes that live in plant roots, the company delivers biomolecules that transform plants into living tools for pollutant removal and critical mineral recovery. The approach is rapid, low-cost, and works across plant species without genetic modification.

Founded by Johns Hopkins scientists John Sittmann, PhD, and Tom Curtis, PhD, the company holds a patent-pending platform and early partnerships in mining and energy. Deep Root BioLabs aims to make environmental restoration scalable, profitable, and regenerative.

Forage Evolution is building the next-generation workhorse for biotechnology. For decades, the field has relied on E. coli—a slow, manual system that limits how quickly scientists can design and test new biology.

Forage has engineered Vibrio natriegens, the fastest-growing organism on Earth, to actively take up DNA, creating the first cell that can “listen” for genetic instructions. Their patent-pending Active DNA Uptake system connects seamlessly with DNA synthesis tools, accelerating molecular workflows by up to 60%.

By transforming living cells into responsive, programmable systems, Forage Evolution is redefining how humans communicate with biology—and unlocking a new era of speed, scalability, and creativity in the bioeconomy.

Xias Bio is a biotechnology company focused on developing sustainable, animal-free protein alternatives with excellent product-market fit. The company engineers high-performance recombinant proteins that supersede animal-derived proteins such as collagen, keratin, and elastin. Using its proprietary LiteProtein™ platform, Xias Bio creates multifunctional proteins and peptide complexes that combine the functions of several conventional proteins into a single raw ingredient. These products are produced through fermentation, making them scalable, consistent, and environmentally friendly.

Xias Bio’s technology aims to reduce the environmental and ethical impacts associated with legacy sources while offering manufacturers functional, cost-effective ingredients. The company’s initial commercial focus is on cosmetics and personal care, with plans to expand into other sectors their customers operate including biotechnology, agriculture, and potentially pharmaceuticals. Rather than selling directly to consumers, Xias Bio primarily licenses its protein designs to ingredient manufacturers and industry partners.

BioLattice is on a mission to end corneal blindness. Only 1 in 70 patients who need cornea tissue get access to it. Globally 2 million per year suffer from corneal blindness while only 200,000 per year receive vision restoration through corneal transplants. Over 12 million worldwide are on a donor cornea tissue waiting list, and those with access to donor cornea face challenges including a 10% chance of implant failure within year 1. Even with immunosuppressant drops needed after surgery, the chances of rejection still rise to almost 50% by year 15 with the risk of going blind again. Our engineered cornea, CorneaClearTM, is a synthetic room temperature stable material that will restore AND correct vision. CorneaClearTM will disrupt the standard of care of donor cornea tissue usage in full thickness corneal transplants.

Sable is redefining fat reduction through biotechnology. Stubborn pockets of subcutaneous fat—under the chin, on the thighs, and around the arms—often persist despite diet and exercise. Yet today’s topical “slimming” products rely largely on cosmetic actives like caffeine, with little scientific evidence supporting meaningful results.

Born from groundbreaking research at Columbia University Medical Center, Sable’s lead compound, SBL-001, has been shown to selectively target fat cells and reduce their volume by up to 70%. Leveraging advanced formulation science, the company is developing this patented nanomaterial into a line of effective, biotechnology-driven topical slimming creams.

Led by Dr. Daniel Chai, Sable plans a multi-channel launch, including dermatology practices, e-commerce, and luxury retail—bringing clinically grounded fat-reduction technology directly to consumers

Animals can’t tell us when something is wrong, so they suffer in silence. Janus is changing that by listening directly to the brain. Founded by neurotech pioneer Peter Freer and led by consumer tech veteran Shaun Westbrook, Janus is the first neural AI platform for pets that decodes brain signals contactlessly—no electrodes, shaving, or sedation. Using patented neuro-sensing technology, it detects invisible signs of illness, pain, stress, and cognitive decline before symptoms appear, empowering early intervention and healthier lives.

Unlike today’s pet trackers that monitor motion or vitals only after problems arise, Janus reveals what pets feel before symptoms show. Designed for everyday pet owners, it brings cutting-edge neuroscience into the home, turning hidden neural patterns into clear insights and actions. Janus is redefining the human–animal bond, creating a future where our dogs and cats aren’t just cared for, but truly understood.

5h45 is a biotechnology company reinventing how we style and care for hair. Founded by Lea Majerholc after a near-fatal reaction to a chemical straightening treatment, 5h45 was born to end the cycle of toxic, damaging products that dominate an $80 billion market.

The company’s patented silk-based nanofilm forms a biomimetic layer around each hair fiber—shaping, repairing, and protecting it without harm. The result is smooth, frizz-free hair that resists humidity for months, yet remains fully reversible and biodegradable.

Led by scientists from Tufts, Technion, and Prose, 5h45 unites biotechnology and beauty to deliver the first safe, high-performance alternative to keratin and relaxer treatments.

Harmony Baby Nutrition is a biotech-driven company revolutionizing the $100B global infant formula market by creating products that mirror the form and function of human milk. Founded by serial entrepreneur Wendel Afonso, the company leverages deep formulation science to develop hypoallergenic, clean-label formulas using human milk components. Unlike traditional cow’s milk-based formulas that can cause digestive distress for 1 in 5 babies, Harmony’s products are designed to be both highly tolerable and palatable. Supported by $13.5M in funding from top-tier VCs and a team of experts from institutions like Harvard and Nestlé, the company plans to launch its first product, Melodi, an allergy-friendly toddler formula, in Q2 2026. Harmony’s long-term mission is to eliminate the need for parents to compromise on nutrition, providing a superior alternative that helps the next generation thrive.

Glycans are complex sugars that coat proteins and dictate how cells and tissues behave. Glycan-driven mechanisms sit at the core of immune and fibrotic diseases and contribute to up to 25% of global disease burden, yet 96% of FDA-approved drugs target proteins.

Anomer Bio’s proprietary platform integrates multi-omics data, a Nobel Prize-winning research tool and insights from a first-in-class clinical trial to design synthetic sugar therapeutics. These small molecules are orally delivered, penetrate tissues deeply and selectively block the synthesis of disease-driving glycans. The platform has already yielded hit compounds that reprogram glycans better than the baseline for clinical testing.

Founded by researchers from the Francis Crick Institute and Oxford Dr Sophie James and Dr Marcos Burger Ramos, the company’s lead program focuses on Sanfilippo syndrome, a rare disorder caused by pathogenic glycan accumulation. Anomer Bio has secured $800k in dilutive and non-dilutive funding and is raising $1.2M to select a lead candidate ready for IND-enabling studies.

Circadian OS is pioneering circadian therapeutics—a new class of medicine that measures and reprograms the body’s internal clock to improve how time-sensitive treatments work. The company integrates a proprietary blood test with software-driven, personalized light dosing delivered through everyday devices such as iPads. This dual approach restores immune readiness and aligns peak immune activity with drug administration, amplifying the efficacy of therapies like cancer immunotherapy without adding toxicity.

Originating from Nobel Prize–winning circadian biology at Rockefeller University with co-founders Sofia Axelrod (PhD, Rockefeller), Alexandra Saali (MD, Mount Sinai), and Thomas Brennan (PhD, ARCH Venture Partners), Circadian OS is backed by early human data and partnerships with Mount Sinai, Roche, and Cornell.

Moonlight Therapeutics is addressing a life-threatening gap in food allergy care: the lack of safe, practical options that protect patients from accidental exposure to allergens. Current treatments either require daily ingestion with difficult side effects or strict, unrealistic avoidance, leaving millions vulnerable to anaphylaxis.

Moonlight’s solution is MOON101, a first-in-class, 5-minute, at-home microneedle-based desensitization therapy for peanut allergy. The proprietary skin-stamp delivers allergenic proteins directly to immune cells in the skin – the site where allergic responses can be retrained – enabling precise, localized dosing without gastrointestinal risk. This approach has been scientifically validated across multiple published animal studies and is backed by issued U.S. and European patents. Moonlight aims to redefine food allergy treatment by offering a safe, convenient therapy that can meaningfully improve the quality of life for patients and families.

HexemBio is pioneering the world’s first blood stem cell rejuvenation therapy, a breakthrough platform emerging from >15 Millions from NIH. The company has raised $7.5 million in Seed funding and recently held a successful FDA Pre-IND meeting in January 2026 after being granted Orphan Drug Designation. Its technology, published in Nature, has been featured in The New York Times.

The founding team includes 2 MDs, 2 PhDs, and 1 MBA from MIT, Harvard, UC Berkeley, Mayo Clinic, and Boehringer Ingelheim – second-time founders, Y Combinator alumni, and recipients of DARPA, NIH, and U.S. Presidential awards.

HexemBio is backed by Draper VC, SOSV, Seraphim VC, Venture Science, Zentynel, Zaka VC, Innovation Works, Gaingels, Treeo VC, NY Venture. Its advisory includes Robert Langer (Moderna co-founder), Peter Barton Hutt (Moderna board), Joanne Kurtzberg, MD (leading U.S. clinician), David Harris, PhD (founder, first U.S. blood bank), Jens Nielsen, PhD (CEO, BII – $3B Novo Nordisk), and Felipe Sierra, PhD (former Director, Division of Aging, NIA/NIH).

Cayuga Biotech is a clinical-stage company developing novel therapeutics to address hemorrhage by harnessing the body’s innate ability to stop bleeding. Cayuga’s pipeline includes CAY001 (polyP-SNP complex) in development for life-threatening major hemorrhage; CAY002, a discovery-stage program for inherited bleeding disorders, and; a portfolio of additional early-stage programs across the healing continuum.